Metritason

Metritason is a synthetic glucocorticoid historically used in the treatment of a variety of conditions, including rheumatoid arthritis, asthma, and skin disorders. It was first synthesized in the early 1950s and was marketed as a potentially safer alternative to other glucocorticoids available at the time.

Due to its potency and systemic effects, metritason was primarily administered orally or intravenously. It exhibited a rapid onset of action and was effective in reducing inflammation and suppressing the immune system. However, this potency also led to a higher risk of side effects, including adrenal suppression, glucose intolerance, and cardiovascular complications.

As research continued, potential toxic effects and interactions with other medications became clear. Despite initial enthusiasm, metritason's use declined as newer, more targeted glucocorticoids were developed. It is no longer widely prescribed or marketed in many countries.

Human studies have shown distinct pharmacokinetic profiles when metritason is taken orally versus intravenously. Peak blood serum concentrations occurred 1-3 hours after oral administration and 30 minutes to 1 hour after intravenous injection. The drug is metabolized in the liver primarily by glucuronic acid conjugation, with a half-life of several hours, allowing devices to adjust dosing accordingly.

Though metritason was effective in the treatment of specific conditions, the availability of safer glucocorticoids developed later has largely supplanted its use. Today it remains an important historical example of glucocorticoid development in the mid-20th century.